STAT family of transcription factors in breast cancer: Pathogenesis and therapeutic opportunities and challenges
GL Wong, SG Manore, DL Doheny, HW Lo - Seminars in cancer biology, 2022 - Elsevier
Breast cancer is the most commonly diagnosed cancer and second-leading cause of cancer
deaths in women. Breast cancer stem cells (BCSCs) promote metastasis and therapeutic …
deaths in women. Breast cancer stem cells (BCSCs) promote metastasis and therapeutic …
[HTML][HTML] A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer
Background Triple-negative breast cancer (TNBC) is a heterogeneous, aggressive
phenotype of breast cancer with associated chemoresistance. The development of chemo-or …
phenotype of breast cancer with associated chemoresistance. The development of chemo-or …
Triple-negative breast cancer metastasis involves complex epithelial-mesenchymal transition dynamics and requires vimentin
Triple-negative breast cancer (TNBC) is an aggressive subtype associated with early
metastatic recurrence and worse patient outcomes. TNBC tumors express molecular …
metastatic recurrence and worse patient outcomes. TNBC tumors express molecular …
[HTML][HTML] The renaissance of CDK inhibitors in breast cancer therapy: An update on clinical trials and therapy resistance
M Abdelmalak, R Singh, M Anwer, P Ivanchenko… - Cancers, 2022 - mdpi.com
Simple Summary Cyclin-dependent kinase inhibitors (palbociclib (Ibrance), ribociclib
(Kisqali), and abemaciclib (Verzenio)), targeting aberrant cell-cycle activity have been …
(Kisqali), and abemaciclib (Verzenio)), targeting aberrant cell-cycle activity have been …
A synchronized dual drug delivery molecule targeting cancer stem cells in tumor heterogeneity and metastasis
Cancer stem-like cells (CSCs) represent a key barrier to successful therapy for triple-
negative breast cancer (TNBC). CSCs promote the emergence of chemoresistance …
negative breast cancer (TNBC). CSCs promote the emergence of chemoresistance …
A tumor-targeted delivery of oral isoliquiritigenin through encapsulated zein phosphatidylcholine hybrid nanoparticles prevents triple-negative breast cancer
Y Wang, C Zhang, M Xiao, K Ganesan, F Gao… - Journal of Drug Delivery …, 2023 - Elsevier
Abstract Treatment of aggressive triple-negative breast cancer (TNBC) is still challenging.
Isoliquiritigenin (ISL) is a water-insoluble bioactive compound possessing high anti-TNBC …
Isoliquiritigenin (ISL) is a water-insoluble bioactive compound possessing high anti-TNBC …
[HTML][HTML] Endorsement of TNBC biomarkers in precision therapy by nanotechnology
Simple Summary Triple-negative breast cancer (TNBC), the most aggressive and
heterogenous type of cancer, lacks the expression of hormones like estrogen, progesterone …
heterogenous type of cancer, lacks the expression of hormones like estrogen, progesterone …
[HTML][HTML] Development of cyclic peptides targeting the epidermal growth factor receptor in mesenchymal triple-negative breast cancer subtype
Triple-negative breast cancer (TNBC) is an aggressive malignancy characterized by the lack
of expression of estrogen and progesterone receptors and amplification of human epidermal …
of expression of estrogen and progesterone receptors and amplification of human epidermal …
[HTML][HTML] Investigating potential immune mechanisms of trilaciclib administered prior to chemotherapy in patients with metastatic triple-negative breast cancer
AR Tan, J O'Shaughnessy, S Cao, S Ahn… - Breast Cancer Research …, 2023 - Springer
Purpose In a phase II trial in patients with metastatic triple-negative breast cancer (mTNBC;
NCT02978716), administering trilaciclib prior to gemcitabine plus carboplatin (GCb) …
NCT02978716), administering trilaciclib prior to gemcitabine plus carboplatin (GCb) …
[HTML][HTML] Correlation between the Warburg effect and progression of triple-negative breast cancer
S Liu, Y Li, M Yuan, Q Song, M Liu - Frontiers in Oncology, 2023 - frontiersin.org
Triple-negative breast cancer (TNBC) is ineligible for hormonal therapy and Her-2-targeted
therapy due to the negative expression of the estrogen receptor, progesterone receptor, and …
therapy due to the negative expression of the estrogen receptor, progesterone receptor, and …